Josie vs Midi Health
Both treat the same patient — a woman in perimenopause or menopause dealing with metabolic change alongside hormonal symptoms — and both offer GLP-1s and hormone care together. The difference is where each is strongest: Josie on published pricing and format choice, Midi on pharmacy sourcing and insurance.
Last updated August 8, 2026
Side by side
| Dimension | Josie | Midi Health |
|---|---|---|
| Compounded semaglutide price | From $194/month (injection), published before intake | Injectable $165.90-$434 per 4-week supply, published dose by dose |
| Oral / non-injection option | ODT formats for both semaglutide ($226) and tirzepatide ($242) | Sublingual GLP-1s $164-$460 per 4-week supply |
| Pharmacy disclosure | 'A licensed pharmacy or compounding pharmacy' — not named, no 503A/503B | States compounded medication comes from 503B-accredited pharmacies |
| Insurance | Not stated as accepted; assume cash-pay | Insurance-covered visits available for qualifying patients |
| Membership fee | None advertised | None |
| Hormone therapy | HRT from $89/month alongside the GLP-1 pathway | Menopause care is the core of the service |
| Prescribing language | Consistently conditional — 'may discuss', 'if care is prescribed' | Clinician-led menopause specialists |
| Microdosing | Sells a $189/month microdose 'longevity' protocol with no evidence base | Not offered as a longevity product |
| Price transparency before signup | Complete list of every medication and format, no email required | Complete dose-by-dose price table published |
Highlighted cells indicate the stronger position on that dimension only. Facts are taken from each provider's own published materials and are recorded in full on their individual review pages.
Choose Josie if…
- You want to see every price and format before giving up any details
- You want an oral disintegrating tablet rather than an injection
- You want HRT and GLP-1 care from one provider at a low HRT entry price
Choose Midi Health if…
- You want 503B-accredited pharmacy sourcing, which carries more manufacturing oversight
- You may qualify for insurance-covered visits
- You want menopause specialists rather than a broader telehealth service
Our verdict
Midi has the better clinical supply chain — stating 503B-accredited sourcing is a real advantage over Josie's unnamed 'licensed pharmacy or compounding pharmacy', and insurance-covered visits can materially reduce cost. Josie's strengths are transparency of format and price, genuinely careful prescribing language, and a cheap HRT entry point at $89. Our one firm recommendation applies to Josie specifically: skip the $189 microdose 'longevity' protocol, which has no approved indication, no dosing standard and no supporting trial data, and costs within $5 of full-dose semaglutide.
Frequently asked questions
Does 503B sourcing actually matter?
Yes. A 503A compounding pharmacy prepares medication against individual prescriptions and is regulated primarily by state boards of pharmacy. A 503B outsourcing facility registers with the FDA and must comply with current good manufacturing practice requirements that 503A pharmacies do not. Neither produces an FDA-approved drug, but 503B operates under substantially more manufacturing oversight. Midi stating 503B-accredited sourcing is a meaningful positive; Josie declining to say which applies is the gap in an otherwise transparent service.
Are oral GLP-1 formats as good as injections?
Not established, and worth understanding before paying extra. Both providers offer non-injection routes — Josie an oral disintegrating tablet, Midi a sublingual formulation — and the appeal is obvious, since needle aversion stops many people from ever starting. But these are compounded formulations, not FDA-approved oral products, and their absorption has not been characterised the way the injectable route has. You are paying a premium for a format whose bioavailability is less well established. If you can inject, the injectable route rests on far more evidence.
Should I treat menopause symptoms and weight together?
They genuinely arrive together — the metabolic shift of perimenopause and the symptoms treated by HRT appear in the same years — so a provider who can address both has real practical value. But starting two therapies at once makes it harder to attribute either benefit or side effect, and hormone therapy has its own risk profile around clotting and hormone-sensitive cancers. Ask either provider about starting one and adding the other, and about what monitoring applies to each.
Compare more options
Medical disclaimer
This comparison is for informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Only a licensed clinician who has evaluated you can decide whether any medication is appropriate. Pricing, medication availability, pharmacy partners and policies change frequently and vary by state — verify everything directly with the provider before purchasing.